|
1
|
van der Hage JA, van de Velde CJ, Julien
JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative
chemotherapy in primary operable breast cancer: results from the
European Organization for Research and Treatment of Cancer trial
10902. J Clin Oncol. 19:4224–4237. 2001.
|
|
2
|
Singletary SE: Neoadjuvant chemotherapy in
the treatment of stage II and III breast cancer. Am J Surg.
182:341–346. 2001.
|
|
3
|
Wolmark N, Wang J, Mamounas E, Bryant J
and Fisher B: Preoperative chemotherapy in patients with operable
breast cancer: nine-year results from National Surgical Adjuvant
Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 96–102.
2001.
|
|
4
|
Bear HD, Anderson S, Smith RE, et al:
Sequential preoperative or postoperative docetaxel added to
preoperative doxorubicin plus cyclophosphamide for operable breast
cancer: National Surgical Adjuvant Breast and Bowel Project
Protocol B-27. J Clin Oncol. 24:2019–2027. 2006.
|
|
5
|
Müller HM, Widschwendter A, Fiegl H, et
al: DNA methylation in serum of breast cancer patients: an
independent prognostic marker. Cancer Res. 63:7641–7645. 2003.
|
|
6
|
Göbel G, Auer D, Gaugg I, et al:
Prognostic significance of methylated RASSF1A and PITX2 genes in
blood- and bone marrow plasma of breast cancer patients. Breast
Cancer Res Treat. 130:109–117. 2011.
|
|
7
|
Sharma G, Mirza S, Parshad R, et al:
Clinical significance of promoter hypermethylation of DNA repair
genes in tumor and serum DNA in invasive ductal breast carcinoma
patients. Life Sci. 87:83–91. 2010.
|
|
8
|
Lo PK and Sukumar S: Epigenomics and
breast cancer. Pharmacogenomics. 9:1879–1902. 2008.
|
|
9
|
Martens JW, Margossian AL, Schmitt M,
Foekens J and Harbeck N: DNA methylation as a biomarker in breast
cancer. Future Oncol. 5:1245–1256. 2009.
|
|
10
|
Yamamoto N, Nakayama T, Kajita M, et al:
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and
RARβ2 in serum DNA of patients with breast cancer by a newly
established one-step methylation-specific PCR assay. Breast Cancer
Res Treat. 132:165–173. 2012.
|
|
11
|
Fujita N, Nakayama T, Yamamoto N, et al:
Methylated DNA and total DNA in serum detected by one-step
methylation-specific PCR is predictive of poor prognosis for breast
cancer patients. Oncology. 83:273–282. 2012.
|
|
12
|
Sharma G, Mirza S, Parshad R, Gupta SD and
Ralhan R: DNA methylation of circulating DNA: a marker for
monitoring efficacy of neoadjuvant chemotherapy in breast cancer
patients. Tumour Biol. 33:1837–1843
|
|
13
|
Avraham A, Uhlmann R, Shperber A, et al:
Serum DNA methylation for monitoring response to neoadjuvant
chemotherapy in breast cancer patients. Int J Cancer.
131:E1166–E1172
|
|
14
|
Goldhirsch A, Glick JH, Gelber RD, Coates
AS and Senn HJ: Meeting highlights: International Consensus Panel
on the treatment of primary breast cancer. Seventh International
Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin
Oncol. 19:3817–3827. 2001.
|
|
15
|
Goldhirsch A, Wood WC, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Meeting highlights: updated
international expert consensus on the primary therapy of early
breast cancer. J Clin Oncol. 21:3357–3365. 2003.
|
|
16
|
Goldhirsch A, Glick JH, Gelber RD, Coates
AS, Thürlimann B, et al; Panel members. Meeting highlights:
international expert consensus on the primary therapy of early
breast cancer 2005. Ann Oncol. 16:1569–1583. 2005.
|
|
17
|
Arai T, Miyoshi Y, Kim SJ, et al:
Association of GSTP1 expression with resistance to docetaxel and
paclitaxel in human breast cancers. Eur J Surg Oncol. 34:734–738.
2008.
|
|
18
|
Robbins P, Pinder S, de Klerk N, et al:
Histological grading of breast carcinomas: a study of interobserver
agreement. Hum Pathol. 26:873–879. 1995.
|
|
19
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011.
|
|
20
|
Fleischhacker M and Schmidt B: Circulating
nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta.
1775:181–232. 2007.
|
|
21
|
Kowalewska M, Nowak R and Chechlinska M:
Implications of cancer-associated systemic inflammation for
biomarker studies. Biochim Biophys Acta. 1806:163–171. 2010.
|
|
22
|
Matuschek C, Bölke E, Lammering G, et al:
Methylated APC and GSTP1 genes in serum DNA correlate with the
presence of circulating blood tumor cells and are associated with a
more aggressive and advanced breast cancer disease. Eur J Med Res.
15:277–286. 2010.
|
|
23
|
Van der Auwera I, Elst HJ, Van Laere SJ,
et al: The presence of circulating total DNA and methylated genes
is associated with circulating tumour cells in blood from breast
cancer patients. Br J Cancer. 100:1277–1286. 2009.
|
|
24
|
Schwarzenbach H, Alix-Panabières C, Müller
I, et al: Cell-free tumor DNA in blood plasma as a marker for
circulating tumor cells in prostate cancer. Clin Cancer Res.
15:1032–1038. 2009.
|
|
25
|
Mathiesen RR, Borgen E, Renolen A, et al:
Persistence of disseminated tumor cells after neoadjuvant treatment
for locally advanced breast cancer predicts poor survival. Breast
Cancer Res. 14:R117
|
|
26
|
Xenidis N, Ignatiadis M, Apostolaki S, et
al: Cytokeratin-19 mRNA-positive circulating tumor cells after
adjuvant chemotherapy in patients with early breast cancer. J Clin
Oncol. 27:2177–2184. 2009.
|
